Some strengths of our report include the use of CRISPR-Cas9 gene editing technology to precisely introduce a defined genetic modification in Card9 without affecting adjacent sequences, and the use of a well-established intratracheal infection model to comprehensively characterize lung inflammatory and immune responses. Here, CARD9 is linked to infection.